{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:41:20Z","timestamp":1760888480848,"version":"3.37.3"},"reference-count":34,"publisher":"Informa UK Limited","issue":"12","funder":[{"name":"Theravance, Inc."},{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.2217\/fmb.10.138","type":"journal-article","created":{"date-parts":[[2010,11,17]],"date-time":"2010-11-17T12:10:52Z","timestamp":1289995852000},"page":"1765-1773","source":"Crossref","is-referenced-by-count":12,"title":["ATLAS Trials: Efficacy And Safety Of Telavancin Compared With Vancomycin For The Treatment Of Skin Infections"],"prefix":"10.1080","volume":"5","author":[{"given":"Steven L","family":"Barriere","sequence":"first","affiliation":[{"name":"Theravance, Inc.,\r          901 Gateway Boulevard,\r          South San Francisco, CA94080, USA Tel.:  Fax:"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,12,14]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2004.10.001"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.159.10.980"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1009.040069"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/421946"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/345476"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/367653"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/379321"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/109629602761624225"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055356"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh185"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/379022"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/507923"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/499367"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/499815"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025025"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01388-06"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00005"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"e_1_3_2_21_1","first-page":"M7","volume-title":"Approved Standard \u2013 Sixth Edition.","year":"2006","unstructured":"Clinical and Laboratory Standards Institute (CLSI): Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard \u2013 Sixth Edition. CLSI, Wayne, PA, USA, M7\u2013A6 (2006)."},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/513203"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01398-07"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.3.347"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl235"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01244-08"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.195-201.2005"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn273"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.788-790.2006"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01750-09"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.862-867.2006"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1086\/429914"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G728"},{"key":"e_1_3_3_2_1","unstructured":"Vibativ\u2122 prescribing information. Theravance Inc. CA USA; and Astellas Pharma US Inc. IL USA (2009) www.astellas.us\/docs\/us\/VIBATIV_PI_Final.pdf (Accessed 19March2010)"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb.10.138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:40:22Z","timestamp":1719124822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb.10.138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.2217\/fmb.10.138"],"URL":"https:\/\/doi.org\/10.2217\/fmb.10.138","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"type":"print","value":"1746-0913"},{"type":"electronic","value":"1746-0921"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}